Pharma’s Almanac Named Model Medicines a Small Biotech to Watch

Pharma’s Almanac Named Model Medicines a Small Biotech to Watch

Pharma’s Almanac Named Model Medicines a Small Biotech to Watch

Pharma’s Almanac Named Model Medicines a Small Biotech to Watch

Pharma’s Almanac included Model Medicines in its April 2025 list of “Five Small Biotechs to Watch,” recognizing the company’s AI-driven approach to drug discovery and therapeutic development.
Illustrated portrait of Patrick ONeill, Head of Partnerships and Investor Relations of Model Medicines

Patrick ONeill

Head of Partnerships and Investor Relations

Pharma’s Almanac featured Model Medicines among five emerging biotechs to watch, spotlighting the company’s use of GALILEO™ to accelerate drug discovery and identify new therapeutic opportunities. The feature placed Model Medicines alongside a select group of small biotechs advancing differentiated approaches across drug development, with particular attention to companies using new technologies to address long-standing challenges in pharma innovation.